GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Verona Pharma PLC (NAS:VRNA) » Definitions » Beta

Verona Pharma (Verona Pharma) Beta : -0.25 (As of May. 01, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Verona Pharma Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2024-05-01), Verona Pharma's Beta is -0.25.


Verona Pharma Beta Historical Data

The historical data trend for Verona Pharma's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verona Pharma Beta Chart

Verona Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.64 0.84 0.47 -0.20

Verona Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.47 -0.02 -0.03 -0.12 -0.20

Competitive Comparison of Verona Pharma's Beta

For the Biotechnology subindustry, Verona Pharma's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Verona Pharma's Beta Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Verona Pharma's Beta distribution charts can be found below:

* The bar in red indicates where Verona Pharma's Beta falls into.



Verona Pharma Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.


Verona Pharma  (NAS:VRNA) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Verona Pharma Beta Related Terms

Thank you for viewing the detailed overview of Verona Pharma's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.


Verona Pharma (Verona Pharma) Business Description

Traded in Other Exchanges
Address
3 More London Riverside, London, GBR, SE1 2RE
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma. The company is engaged in pharmaceutical development.
Executives
Martin Edwards director 15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803
David R Ebsworth director C/O CURAGEN CORP, 555 LONG WHARF DR. 11TH FL., NEW HAVEN CT 06511
Kathleen A. Rickard officer: Chief Medical Officer C/O VERONA PHARMA PLC, 3 MORE LONDON RIVERSIDE, LONDON X0 SE1 2RE
Christina Ackermann director C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Claire Poll officer: General Counsel C/O VERONA PHARMA PLC, 3 MORE LONDON RIVERSIDE, LONDON X0 SE1 2RE
Mark W Hahn officer: Chief Financial Officer 6340 QUADRANGLE DRIVE, SUITE 100, CHAPEL HILL NC 27517
David Zaccardelli director, officer: President and CEO 300 TRI STATE INTERNATIONAL, SUITE 272, LINCOLNSHIRE IL 60069
Orbimed Advisors Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Rishi Gupta director, 10 percent owner C/O CHEMOCENTRYX, INC., 850 MAUDE AVENUE, MOUNTAIN VIEW CA 94043
Access Industries Holdings Llc 10 percent owner C/O ACCESS INDUSTRIES MANAGEMENT, LLC., 730 FIFTH AVENUE, 20TH FLOOR, NEW YORK NY 10019
Ai Biotechnology Llc 10 percent owner C/O ACCESS INDUSTRIES, INC., 40 WEST 57TH STREET, 28TH FLOOR, NEW YORK NY 10019
Access Industries Management, Llc 10 percent owner 730 FIFTH AVENUE, NEW YORK NY 10019
Len Blavatnik 10 percent owner C/O ACCESS INDUSTRIES, 730 FIFTH AVENUE, NEW YORK NY 10019
James Aloysius Brady director C/O VERONA PHARMA PLC, 3 MORE LONDON RIVERSIDE, LONDON X0 SE1 2RE
Lisa Deschamps director C/O VERONA PHARMA PLC, 3 MORE LONDON RIVERSIDE, LONDON X0 SE1 2RE